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Abstract
Background: The vascular type represents a very rare, yet the clinically most fatal entity of Ehlers-Danlos syndrome
(EDS). Patients are often admitted due to arterial bleedings and the friable tissue and the altered coagulation
contribute to the challenge in treatment strategies. Until now there is little information about clotting
characteristics that might influence hemostasis decisively and eventually worsen emergency situations.
Results: 22 vascular type EDS patients were studied for hemoglobin, platelet volume and count, Quick and
activated partial thromboplastin time, fibrinogen, factor XIII, von Willebrand disease, vitamin D and platelet
aggregation by modern standard laboratory methods. Results show a high prevalence of over 50 % for platelet
aggregation disorders in vascular type EDS patients, especially for collagen and epinephrine induced tests, whereas
the plasmatic cascade did not show any alterations. Additionally, more than half of the tested subjects showed low
vitamin D serum levels, which might additionally affect vascular wall integrity.
Conclusion: The presented data underline the importance of detailed laboratory screening methods in vascular
type EDS patients in order to allow for targeted application of platelet-interacting substances that might be of
decisive benefit in the emergency setting.
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Background
Ehlers-Danlos syndrome (EDS) is a rare connective tissue
disorder with multitude heterogeneous symptoms. The
estimated overall incidence is approx. 1:5000 [1]. Muta-
tions of fibrillar collagens (I, II, III, IV, V, VI, IX and XII)
or enzymes involved in their biosynthesis (i.e. PLOD1,
CHST14) are responsible for the multi-systemic affection
involving skin, ligaments, muscles, vessels, hollow organs,
eyes and teeth [2, 3]. The rarity, although good in itself,
impedes both, evidence or eminence-guided treatment,
especially in emergency situations.
Classifications of EDS based on symptoms in the
Berlin Nosology from 1986 aimed to facilitate diagnosis
and genetic counseling and to provide treatment sugges-
tions. In the currently applicable Villefranche Classifica-
tion from 1997 these were additionally linked to the
respective genetic mutations [3, 4].
Vascular type EDS, formerly known as EDS type IV,
comprises approximately 8 % of all EDS patients [5].
Mutations in COL3A1 cause stigmata like thin translucent
skin with visible venous pattern, congenital clubfoot or
hip dislocation and characteristic facial appearance. How-
ever, vascular fragility and abnormal vessel structure,
cause the characteristic symptoms like easy bruising,
severe varicosities, arterial dissection or aneurysm forma-
tion and eventual arterial or intestinal rupture, that can
lead to fatal consequences and a reduced life span of pa-
tients [2, 5, 6].
Current treatment is symptomatic only, since no causal
therapy exists. The gold standard “conservative first” is,
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however, of limited advice, for most admissions are due
to emergency bleedings, involving mid-size and big ar-
teries in thoracic or abdominal position, including the
aorta [7, 8]. Accordingly, mortality rates after emer-
gency surgery are high and have only modestly declined
from 40–60 % to around 30–40 % with evolving endo-
vascular arterial repair [8–10].
Moreover, secondary intervention rates up to 50 %
due to access site, as well as unrelated secondary bleed-
ing complications add to an unacceptable morbidity
and mortality rate in this subset of patients [8, 9, 11,
12]. The critical points impairing surgical outcome are
vascular fragility, probably worsened by circulating col-
lagenases during acute events of bleeding, and a defi-
cient coagulation cascade impairing primary healing
[13, 14]. Therefor, desmopressin administration prior to
surgery was recommended in EDS patients [15]. But
whether defects of pro-coagulant factors or misleading
platelet-collagen-interactions are causative for deficient
coagulatory properties is still unclear and little is known
about the coagulation cascade in vascular type EDS in
particular [16].
We therefore aimed to investigate hemostasis in vas-
cular type EDS patients under normal conditions by
standard laboratory means in order to reveal coagula-
tion defects, eventually allowing a targeted therapy to
breach the fatal course of acute bleedings in this subset
of patients.
Methods
Patient identification and sample analysis
Vascular type EDS patients were identified and invited
with support of a nationwide patients’ self-help group,
the German National EDS Initiative, in accordance with
the national regulations for protection of data privacy.
Inclusion criterion was affection by vascular type EDS.
All participants were in good condition (Karnofsky Index
>90 %). The study was in accordance with the declaration
of Helsinki and approved by the local ethics committee
(University Hospital of Würzburg) and with patients’
informed and written consent. The study was conducted
between January 1st and December 31st 2015.
Blood was drawn from a cubital vein with free flow
after initial stasis. In order to allow immediate analysis
of the samples, seven different laboratories (affiliations
no. 3, 4, 5, 6, 9, 10, 11) across Germany participated in
the study. All tests are standardized, commercially avail-
able products with defined and validated normal ranges
and criteria for pathologic results. Normal measurement
ranges and availability of single test methods varied
slightly among the participating laboratories (Additional
file 1: Table S1 and Additional file 2: Table S2). All labora-
tories are subject to routine quality control and daily/
weekly calibration of their test series.
Basic test methods
Automated analyzers did hemograms, which delivered
hemoglobin (Hb), platelet count and optional thrombo-
cyte volume. C-reactive protein (CRP) serum concentra-
tion was measured as a reference value to interpret test
results and exclude acute inflammatory processes. Pro-
thrombin time according to Quick and activated partial
thromboplastin time (PTT) for the extrinsic and intrin-
sic coagulation pathway were measured by a turbidimet-
ric assay. Depending on the laboratory Fibrinogen was
measured either by the Clauss-method or as prothrom-
bin time derived fibrinogen (all Quick values were within
normal range, Additional file 1: Table S1).
Factor XIII
Factor XIII (FXIII) was measured either by a chromogenic
assay or ELISA (enzyme linked immunosorbent assay)
since it is not detected elsewhere, yet has a distinctive
function in fibrin crosslinking.
Von Willebrand diagnostics
Von Willebrand factor (vWF) was assessed by two dif-
ferent assays. Latex Immunoassay or ELISA-methods
were applied to measure vWF-antigen (vWF:ag) and
vWF-activity (vWF:act). Reduced vWF (low vWF:ag)
and reduced activity (low vWF:act) in synopsis with a
clinical bleeding phenotype was thus defined as pos-
sible von Willebrand syndrome (vWS). The patients’
blood group was determined in order to allow correct
assess correct normal ranges.
Vitamin D
Vitamin D concentration was measured from plasma
samples by high performance liquid chromatography
(HPLC) or enzyme immunoassay (EIA).
ROTEM®
The ROTEM® is a haemostasis analyzer, that measures
kinetic changes of the clot elasticity of whole blood
samples [17]. It is provided by the TEM group (Basel,
Switzerland) (http://www.rotem.de/en) and allows quan-
titative and qualitative assessment by measuring differ-
ent parameters of the clot status of the blood sample. In
our study we applied the in-tem® (fast assessment of clot
formation, fibrin polymerization and fibrinolysis via the
intrinsic pathway), ex-tem® (fast assessment of clot for-
mation, fibrin polymerization and fibrinolysis via the ex-
trinsic pathway), fib-tem® (fast analysis without platelets;
qualitative assessment of fibrinogen status) and ap-tem®
(fast detection of lysis when compared with ex-tem via
fibrinolysis inhibition).
Busch et al. Orphanet Journal of Rare Diseases  (2016) 11:111 Page 2 of 8
PFA100®
The PFA-100® analyzes platelet function from citrate
blood by aspiration at high shear rates through dispos-
able cartridges containing an aperture within a mem-
brane coated with collagen (Col) plus either epinephrine
(EPI) or ADP (ADP). These agonists induce platelet
adhesion, activation and aggregation and lead to occlu-
sion of the membrane and cessation of the blood under
normal conditions. The resulting time until cessation is
called closure time (CT) (http://www.practical-haemos-
tasis.com/Platelets). CT-Prolongation is thus suggestive
of deranged primary hemostasis such as thrombocyte
dysfunction by impaired activation and cross-linking or
vWS. Requirements are a thrombocyte count >80x106/
mm2 and a hematocrit >35 %.
Light transmission aggregometry by Born
Born aggregometry is based on the principle of light
transmission aggregometry. Platelet rich plasma is
stirred in a cuvette and different agonists are added to
induce aggregation. Aggregated platelets absorb less light
and transmission detected by a photocell thus increases
(http://www.practical-haemostasis.com). Agonists are colla-
gen (Col), epinephrine (EPI), adenosintriphosphate (ADP)
and ristocetin (Rist). Additionally, thrombin, thrombox-
aneA2 and different agonist concentrations can be
used. This multiple testing allows measurement of
aggregation, shape change of platelets whilst activation
and degranulation.
Values are normally displayed in percentage of trans-
mitted light compared to a control probe (blank) with
platelet poor plasma set to 100 % light transmission. Re-
sults below the normal range thus indicate disturbed
aggregation of platelets.
Results
Vascular type EDS patients have heterogeneous
symptoms and genetics
22 individuals with the diagnosis of vascular type EDS
were enrolled in the study, including fourteen females
and eight males (median age 37 ± 16 years). Among
them ten patients descended from three families (family
A: ID5 and 6; family B: ID16-19; family C: ID11-14) and
another three participants reported EDS symptoms in
first-degree relatives not enrolled in the study (Table 1).
Major and minor symptoms varied tremendously,
with abnormal bleedings, aneurysm formation, un-
usual hemorrhage and also non-vascular EDS symp-
toms. Eleven participants had defined mutations in
COL3A1, three were diagnosed with an EDS specific
skin biopsy by electron microscopic examination and
eight were diagnosed by clinical evaluation of a gen-
eticist (Table 1).
Blood count and plasmatic coagulation are not altered in
vascular type EDS
Hemograms showed no alterations for Hb (13.6 ±
1.1 mg/dL; different normal ranges for males and fe-
males were respected – data not shown) and platelet
count (276 ± 55.4×106/mm2). Platelet volume (9.9 ±
0.4 fL) was available from eleven individuals, and only
one patient (ID8) showed an aberrant volume of 5.8 fL.
CRP was under the threshold of 0.5 mg/dL in all patients
(Additional file 1: Table S1).
Prothrombin time, PTT, Fibrinogen and FXIII-levels
represented plasmatic coagulation. Measurements were
performed in almost every patient. Quick (97.4 ± 14.3 %)
and PTT (30.6 ± 3.4 s) showed normal results for almost
all participants. Fibrinogen (2.8 ± 0.6 g/L) and FXIII
(114.7 ± 23.5 μg/dL) showed borderline levels for only
one patient each, but were within normal ranges other-
wise (Additional file 1: Table S1). Additional ROTEM®
analysis was performed to study clot formation and fibrin-
olysis within the first subjects enrolled in the study – was,
however, abandoned due to high costs or un-availability
(data not shown).
Von Willebrand factor diagnostics were available for
thirteen patients (Additional file 3: Figure S1/Additional
file 2: Table S2). One patient (ID8) showed reduced values
and along with a clinical bleeding diathesis was assumed
to suffer from a mild form of vWS. Patient ID3 showed
abnormally high values and was supposed to eventually
suffer from a collagen-receptor associated platelet disorder
(assumption by the respective laboratory consultant). The
laboratory diagnosis of subnormal vWF-values was thus
made in only 1 out of 13 patients.
Platelet function is impaired in vascular type EDS
All enrolled individuals were screened for thrombocyte
function by either PFA100® or light transmission aggre-
gometry according to Born, depending on availability.
For eight patients both were available.
In total, eleven of 22 patients (50 %) showed impaired
aggregation, especially after induction with epinephrine
(EPI) and collagen (Col) in at least one of two methods
(Fig. 1). Additional four patients showed abnormal re-
sults of unclear significance. Six patients showed aber-
rant values in ADP interaction. From eight patients, in
whom both test methods were available, six showed co-
herent results.
Vascular symptoms and thrombocyte dysfunction vary
within families
Three families with more than one member were enrolled.
Families A and C had mutations in COL3A1, identically
found in all affected members (Table 1). The index person
in family B was diagnosed by clinical phenotype by a
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Table 1 Characteristics of the study population: method of diagnosis shows either the mutation in COL3A1 if found, diagnosis by EDS specific electron microscopy of
antebrachial skin biopsy or clinical phenotype evaluated by a geneticist. Major and minor symptoms include EDS and especially vascular type EDS specific symptoms based
patients’ reports. Familial involvement shows positive family history (yes) in patients and A, B, C refer to distinct families, where more than one member participated in the study
(Fig. 2). Medication shows daily and occasional drugs at the time of investigation. (y = years, f = female, m =male, SAB = subarachnoideal bleeding)




1 f 39 clinical - (uncomplicated delivery) yes Celiprolol
2 f 45 c3508G > A (p.G1170S) hemorrhage (mother/sister had lethal internal bleedings) yes -
3 f 44 Col3A1 c.1804C > A hemorrhage,
hypermenorrhea
(sister/niece have same vasc EDS mutation) yes Thyroxine, Venlafaxine
4 m 52 skin biopsy cranial aneurysm, SAB - - ASS, Metoprolol, Amiodarone
5 m 43 COL3A1:c.{973G > T};{=} cranial aneurysm - A -
6 m 13 COL3A1:c.{973G > T};{=} - hypermobility A -
7 f 22 c.2295_2312delTCCTATTGGTCCTCCTGG,p,lle767_Pro772del vertebral aneurysm hypermenorrhea - evtl Tranexamic acid
8 f 36 clinical - hypermobility - Thyroxine
9 m 53 clinical - multiple hernia - -
10 f 25 skin biopsy internal bleeding hypermobility,kissing spleen,varicose veins,valve
insuffic
- Tramadol,Bisoprolol,Duloxetine
11 f 75 COL3A1:IVS16 + 1G > A cervical av-istula hemorrhage, varicose veins, hypermobility C -
12 f 46 COL3A1:IVS16 + 1G > A kidney infarction, SAB hemorrhage, hematoma lower extremity,
hypermobility
C -
13 f 55 COL3A1:IVS16 + 1G > A SAB hypermobilita C -
14 f 29 COL3A1:IVS16 + 1G > A - spina bifida, hydrocephalus, hypermobility C -
15 f 41 clinical atrial septum aneurysm hemorrhage, hypermobility, mitral valve reflux - Nebivolol,Kodein,Prednisolon
16 f 50 skin biopsy, negative
Col5A/Col3A testing
hemorrhage (six uncomplicated deliveries) B -
17 m 19 clinical gastric perforation hemorrhage B -
18 m 8 clinical hemorrhage impaired wound healing B -
19 m 9 clinical - facial stigmata of EDS B -
20 m 50 Col3A1 c.3544G > A retroperitoneal hemotoma - - -
21 f 25 Col3A1c.1258G > C carotid dissection, stroke contralateral asymptomatic dissection - -














geneticist, as screening for COL3A1/COL5A1 mutations
and analysis of skin biopsy did not show clear results.
Symptoms or alterations in coagulation parameters
varied substantially, even within genetically uniform
families. In family A the phenotype of EDS by facial ap-
pearance was much more pronounced in the son than
the father along with clear signs of platelet dysfunction
in the offspring (Fig. 1). In contrast, members of family
B were more similar in phenotype and symptoms and
showed similar alterations in PFA100® measurements
(Additional file 2: Table S2). PFA100® measurements,
with prolongation of closure-time after EPI induction,
were also very similar in family C, symptoms and pheno-
type, however, differed notably between generations.
Low Vitamin D serum levels were found in vascular type
EDS patients
Serum Vitamin D level was additionally available in
fourteen individuals investigated. 57 % were found to
have low and critically low values (Fig. 3). One patient
(ID8) was below threshold, despite current oral substi-
tution (Additional file 2: Table S2). No patient reported
any form of kidney or liver disease that might influence
Vitamin D biosynthesis.
Discussion
This is, to our best knowledge, the first study to analyze
plasmatic and cellular coagulation in a unique number
of 22 vascular type EDS affected individuals.
EDS reports are generally based on case scenarios and
very few studies include bigger number of patients, gen-
erally from different EDS subtypes [11, 15, 16, 18, 19].
Concordantly, evidence for coagulation disorders associ-
ated with the disease comes from surgical cases and var-
iances in the female reproduction cycle [20–22]. In 1991
Anstey et al. conducted a study in 51 patients of different
EDS types and revealed heterogeneous abnormalities in
platelet aggregation and plasmatic coagulation [16].
Here, we investigated exclusively vascular type EDS and
reveal dysfunctional platelets as the most prominent
disorder with a prevalence of 50 % based on single
time-point blood analysis and a corresponding clinical
hemorrhagic diathesis (Table 1). Especially thrombocyte
stimulation by collagen, epinephrine and ADP was altered
(Fig. 1/Additional file 2: Table S2). Epinephrine is a weak
agonist itself, but an important catalyzer of aggregation
after initial degranulation. Thus prolongation of stable
aggregates might be seriously affected.
The study’s biggest limitation is the observational char-
acter based on single time-point measurements at differ-
ent laboratories. Nationwide inclusion of patients and
immediate sample analyses demand the participation of
diverse institutes, and the use of modern, standardized test
methods with clearly defined pathological ranges copes
with this limitation, as the validation of results for eight
patients with two functional platelet tests could demon-
strate. Confounding bias in pre-analytics was tried to
exclude as much as possible by evaluation of disturbing
values. Additionally, analysis should be broadly available
and not restricted to specialized laboratories or experi-
mental methods.
Our findings are coherent with previously published
EDS cases [16, 18, 23]. In pilot studies from the 1970s
Deliyannis et al. and Karaca et al. were able to show
reduced aggregation of platelets from control patients
with collagen from affected patients and vice versa.
Arneson et al. could restore impaired aggregation by
addition of soluble fibronectin, an extracellular matrix
glycoprotein, in experimental studies [24–26]. Electron
microscopic examination of platelets has suggested
Fig. 1 Platelet function diagnosis: The graphs show qualitative alterations in platelet function diagnosis by PFA100® (upper) or light transmission
aggregometry (lower). Bold red signs demonstrate deviation from the normal range (dotted line). Bleeding time is reported in seconds (s), higher
values thus indicating an abnormal long time till aggregation. Born Aggregation is reported in percentage of a normal probe with no
aggregation and complete light transmission, higher values thus indicating impaired aggregation. Abbreviations in brackets indicate stimulating
substances for test: EPI = epinephrine, ADP = adenosintriphosphate, Col = collagen; Rist = ristocetin; The quantitative values for each patient and
test are depicted in Additional file 2: Table S2
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altered distribution and function of granules [27–29].
Additionally, thrombocyte derived growth factors might
influence COL3A1 expression in non-vascular tissues
[30]. Whether our results are due to dysfunctional re-
ceptor expression or impaired degranulation could not
be verified in this study, yet warrants further dedicated
research.
Based on the cohort size we can safely exclude other
factors to noticeably influence coagulation, like
thrombocyte volume, FXIII deficiency, vWS, or plas-
matic coagulation, as reflected by normal Quick and
PTT [15, 31–33]. Normal screening tests, however, can-
not exclude mild deficiencies or functional impairment
[34, 35].
Since detailed coagulation analysis is not available in
emergency situations, evidence for targeted substitution
must come from investigations under normal conditions.
Our study provides evidence for the application of
thrombocyte- and clot-formation-directed substances in
case of arterial bleedings. The use of desmopressin, tran-
examic acid, activated factor VII, factor VIII and platelet
transfusion have been reported in EDS [15, 18, 33, 36].
Experimental data, however, only exist for desmopressin,
shown to restore normal bleeding time in a total of 21
children with undefined types of EDS in two studies [15,
37]. This effect is most likely due to an increase in FVIII
and vWF from endothelial reservoirs, although in-vitro
experiments have also suggested a direct effect on
thrombocyte granules [29, 38].
A clear clinical type assignation in EDS is very difficult
since the peculiarity of symptoms varies notably among
patients and is only partly reflected by the genotype, as
observed in our cohort (Table 1, Fig. 2). Variability
within families has been described before, but until now
not for coagulation defects [2, 3]. Our results from three
different families with a total of ten members suggest,
that there is no correlation of genotype, clinical symp-
toms and eventual coagulation disorder, are, however,
limited by the small number (Fig. 2). Nevertheless a ded-
icated family evaluation is advisable whenever an index
person is diagnosed.
Of special interest are the low serum levels of Vitamin D
in 8 of 14 tested individuals, which has never been investi-
gated in EDS before (Fig. 3/Additional file 2: Table S2).
Fig. 2 Pedigrees of enrolled families: In family A father and son are
affected by vascular type EDS, daughter and mother are not. The father
(ID5) was the index person. In family B the mother (ID16) was the index
person. She and three of her sons were enrolled in the study. Her
brother is diagnosed having a heart aneurysm but could not be
enrolled in the study. In family C one daughter was the index person
(ID12). She, her sister, the mother and the niece were enrolled. Her
brother died on a ruptured abdominal aortic aneurysm at young age.
(square =male; circle = female; filled = affected/diseased; empty = no
symptoms occurred; crossed out = deceased; numbers refer to patient
ID in other figures and tables; patients with number assigned on the
right side indicate family members enrolled in the study)
Fig. 3 Vitamin D serum levels: The graph shows qualitative alterations in Cholecalciferole serum levels. Bold red signs indicate deviation from the
normal range (dotted line). The quantitative values for each patient and test are depicted in Additional file 2: Table S2
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There is clear evidence for impaired bone mineralization
and abnormal osseous structure by bone mineral density
and x-ray examination from independent studies [39–
41]. Furthermore, characteristic EDS-symptoms, like
chronic pain, tendon weakness and myopathy, are
closely related to bone integrity [42, 43]. Deficiency has
been epidemiologically associated with cardiovascular
disease, clear molecular mechanisms are, however,
missing [44]. Diagnosis of Vitamin D is fairly cheap and
oral substitution with cholecalciferol well tolerated.
Thus screening of EDS patients for Vitamin D defi-
ciency seems advisable, albeit proof of principle for oral
substitution affecting the vascular phenotype has yet to
be done in a bigger cohort. Additional benefit of oral
substitution in vascular type EDS patients might result from
anti-inflammatory and regenerative effects on chronic low-
grade inflammation of the vasculature [31, 45].
Conclusion
In a detailed functional analysis of plasmatic and cellular
coagulation in a cohort of 22 patients with vascular type
EDS we found a high prevalence of 50 % for thrombo-
cyte dysfunctions. This might severely affect hemostasis
in emergency bleeding situations and require targeted
therapy. Elaborate coagulation screening is thus advis-
able in every, especially vascular type EDS patient, as
well as their relatives and should include modern plate-
let aggregation tests. Additionally, we have analyzed
Vitamin D serum levels for the first time in EDS, show-
ing a deficiency in a respectable number of patients that
might be associated with EDS characteristic symptoms.
Additional files
Additional file 1: Table S1. Blood count and plasmatic coagulation
laboratory results: The table shows the results for each patient, listed to
patient ID according to Table 1, with unit and normal measurement
range. Bold red values show deviation from the normal range. Stroked
out values are not available in the specific laboratory of examination.
(DOCX 74 kb)
Additional file 2: Table S2. von Willebrand, Vitamin D and platelet
diagnostics: The table shows the results for each patient, listed to patient
ID according to Table 1, with unit and normal measurement range in
brackets depending on the respective laboratory where the analysis was
performed. For Vitamin D and functional platelet analysis, normal ranges
differ among those depending on the commercial test used. Bold red
values show deviation from the normal range. Stroked out values are not
available in the specific laboratory of examination (n.a.d. = no applicable
disease). (DOCX 111 kb)
Additional file 3: Figure S1. von Willebrand Syndrome diagnostics: The
graph shows qualitative alterations in vWF diagnosis. Bold red signs
demonstrate deviation from the normal range (dotted line). (TIF 213 kb)
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